A17
A17 is a bile acid analog with anti-non-alcoholic steatohepatitis (NASH) and anti-inflammatory activities. A17 reduces fatty acid (FA) uptake and promotes FA oxidation though inhibiting fatty acid translocase (Cd36) expression and activating AMPKα. A17 can be used for NASH research[1].
Product Specifications
CAS Number
2568186-47-8
UNSPSC
12352211
Target
AMPK
Type
Reference compound
Related Pathways
Epigenetics; PI3K/Akt/mTOR
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/a17.html
Purity
99.4
Solubility
10 mM in DMSO
Smiles
O=CO[C@@H]1[C@]2([H])[C@@](CC[C@]3([C@@]2([H])CC[C@]3([H])[C@H](C)CCC(N[C@H](CO)C(C)C)=O)C)([H])[C@@]4([C@](C[C@@H](CC4)OC=O)([H])C1)C
Molecular Formula
C31H51NO6
Molecular Weight
533.75
References & Citations
[1]Wang Y, et al. A novel bile acid analog, A17, ameliorated non-alcoholic steatohepatitis in high-fat diet-fed hamsters. Toxicol Appl Pharmacol. 2020 Oct 1;404:115169.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
AMPKα
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC041863-100 1x 100 µL
Chromogranin A / CHGA (Neuroendocrine Marker) (rCHGA/777), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
